Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics AG (Nasdaq: CRSP) generates frequent news as a gene editing biopharmaceutical company advancing CRISPR/Cas9-based medicines and related platforms. News coverage commonly highlights progress with CASGEVY, described as the world’s first approved CRISPR-based therapy for eligible sickle cell disease and transfusion-dependent beta thalassemia patients, along with updates on the company’s expanding in vivo and cell therapy pipeline.
Investors and observers following CRSP news can expect regular announcements on clinical trial data, such as Phase 1 and Phase 2 results for programs like CTX310 targeting ANGPTL3 for cardiovascular and cardiometabolic disease, and zugo-cel (zugocaptagene geleucel) in autoimmune diseases and B-cell malignancies. Company press releases also report on regulatory milestones and commercialization developments for CASGEVY across multiple regions, including approvals, reimbursement agreements, and pediatric development plans.
CRISPR Therapeutics’ news flow also includes pipeline and platform updates for in vivo liver editing programs (CTX310, CTX320, CTX321, CTX340, CTX450), SyNTase-based CTX460 for alpha-1 antitrypsin deficiency, and regenerative medicine efforts in Type 1 diabetes. Collaboration announcements with partners such as Vertex Pharmaceuticals, Sirius Therapeutics, and Lilly, as well as participation in major scientific and investor conferences, are additional recurring themes.
On Stock Titan’s CRSP news page, readers can review these press releases and third-party articles in one place, track how clinical, regulatory, and partnership developments evolve over time, and use this information as context when assessing CRISPR Therapeutics’ stock and long-term gene editing strategy.
CRISPR Therapeutics (Nasdaq: CRSP) has appointed Dr. Phuong Khanh (P.K.) Morrow as Chief Medical Officer, effective May 23, 2022. Dr. Morrow brings over a decade of experience in global drug development, particularly in oncology, and will oversee the company's clinical development and regulatory operations. The leadership change aims to enhance CRISPR’s innovative gene-editing therapies. CEO Samarth Kulkarni emphasized her expertise will be essential in advancing their clinical strategy and building the organization.
CRISPR Therapeutics (Nasdaq: CRSP) announced that an abstract detailing safety and efficacy data from the ongoing CTX130 clinical trial for T-cell lymphoma has been accepted for oral presentation at the EHA 2022 Hybrid Congress, taking place June 9-12, 2022. This marks the first presentation of clinical data from the CTX130 program. The abstract, titled The COBALT-LYM Study of CTX130, will be presented by Dr. Swaminathan P. Iyer on June 11, 2022. CTX130 is a gene-edited CAR-T therapy targeting CD70, being investigated in two Phase 1 trials for relapsed/refractory malignancies.
CRISPR Therapeutics (CRSP) reported Q1 2022 financial results, highlighting significant progress in clinical trials. Key milestones include dosing over 75 patients with CTX001 in ongoing Phase 3 trials for beta thalassemia and sickle cell disease, with global regulatory submissions anticipated in late 2022. R&D expenses rose to $118.2 million, reflecting ongoing advancements in its immuno-oncology pipeline. Cash reserves stood at $2.22 billion, down from $2.38 billion in Q4 2021. Net loss for the quarter was $179.2 million, compared to $113.2 million a year prior.
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management team will participate in the 2022 Bank of America Healthcare Conference on May 11, 2022, at 4:40 p.m. PT. A live webcast will be available on the Company's Investors section of the website, with a replay accessible for 14 days post-event. The company focuses on gene-based medicines to tackle serious diseases using its innovative CRISPR/Cas9 platform. CRISPR Therapeutics operates in multiple therapeutic areas, including oncology and rare diseases, with collaborations alongside industry leaders like Bayer and Vertex Pharmaceuticals.
CRISPR Therapeutics (Nasdaq: CRSP) has announced the proposed election of Maria Fardis, Ph.D., MBA, to its Board of Directors at the upcoming annual general meeting. With a strong background in biopharmaceuticals, including her leadership at Iovance Biotherapeutics and Acerta Pharma, Dr. Fardis is expected to enhance the company's ability to advance its gene-based medicines pipeline. CEO Samarth Kulkarni highlighted her extensive experience as a valuable asset for CRISPR Therapeutics as it seeks to address serious medical conditions.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in three key investor conferences in April 2022. These include the 21st Annual Needham Virtual Healthcare Conference on April 12 at 12:45 PM ET, the Canaccord Genuity Horizons in Oncology Virtual Conference on April 14 at 1:00 PM ET, and the 14th Kempen Life Sciences Conference in Amsterdam on April 20 at 3:30 PM CET. Live webcasts will be accessible on the company's website, with a 14-day replay available post-event.
CRISPR Therapeutics focuses on gene-based medicines for serious diseases using its innovative CRISPR/Cas9 technology.
CRISPR Therapeutics (Nasdaq: CRSP) will present an e-poster at the AACR 2022 Annual Meeting from April 8-13, 2022, highlighting its innovative cancer immunotherapy research. The presentation titled “CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells” is set for April 8, 2022. This research emphasizes the potential of CRISPR/Cas9 technology in advancing cancer treatments. As a leader in gene editing, CRISPR Therapeutics aims to develop transformative therapies for serious diseases, collaborating with major firms like Bayer and Vertex Pharmaceuticals.
CRISPR Therapeutics (Nasdaq: CRSP) has announced its participation in several investor conferences in March 2022. The schedules are as follows:
- Cowen 42nd Annual Health Care Conference on March 7 at 10:30 a.m. ET.
- Barclays Global Healthcare Conference on March 17 at 10:15 a.m. ET.
- Oppenheimer 32nd Annual Healthcare Conference on March 24 at 11:00 a.m. ET.
Live webcasts will be available on the company's website, with replays accessible for 14 days post-event.
CRISPR Therapeutics (Nasdaq: CRSP) reported a productive 2021, advancing its gene-editing therapies. More than 70 patients have been dosed with CTX001 for beta thalassemia and sickle cell disease, with regulatory submissions expected in late 2022. The company initiated the pivotal trial for CTX110 targeting B-cell malignancies, expecting further data this year. Financially, total revenue surged to $913.1 million from $0.5 million YoY, driven by Vertex collaborations. However, net loss widened to $141.2 million in Q4 2021, emphasizing the costs of R&D investments.
CRISPR Therapeutics (Nasdaq: CRSP) announced that its senior management team will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 p.m. ET. The event will be accessible via a live webcast on the company’s Investors section of its website. Following the event, a replay will be available for 14 days. CRISPR Therapeutics focuses on developing gene-based medicines using CRISPR/Cas9 technology to address serious diseases, with collaborations alongside industry leaders like Bayer and Vertex Pharmaceuticals.
FAQ
What is the current stock price of Crispr Therapeut (CRSP)?
What is the market cap of Crispr Therapeut (CRSP)?
